Canaan IX L.P., Director, 10% Owner at CytomX Therapeutics, Inc. (CTMX), sold 172,540 shares at $11.07 ($1.9M) on 2016-11-10, disclosed to the SEC on 2016-11-14.
Open-market sale of $1.9M CTMX by Director, 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $11.07 | 27,135 | $300K | 15.6% |
| 2 | $11.07 | 27,135 | $300K | 15.6% |
| 3 | $11.20 | 35,391 | $396K | 20.6% |
| 4 | $11.20 | 35,391 | $396K | 20.6% |
| 5 | $11.21 | 23,744 | $266K | 13.8% |
| 6 | $11.21 | 23,744 |
| $266K |
| 13.8% |
| Total | $11.16 avg | 172,540 | $1.9M | 100% |
| Filing → |
| CTMX | SELL | 2016-11-21 | $526K | — | Filing → |
| CTMX | SELL | 2016-11-16 | $593K | — | Filing → |
| CTMX | SELL | 2016-06-10 | $487K | — | Filing → |